No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Leaping Bio (02157) candidate drug MRG003 has been granted breakthrough designation for the treatment of FDA.
Jingu Wealth News | BeiGene (02157) announced that its candidate drug MRG003 (a monoclonal antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), as well as the company's core product) has recently been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/MNPC). It is reported that BTD is designed to promote and accelerate the development and evaluation of new drugs for the treatment of severe diseases that have preliminary evidence of significant clinical advantages compared to existing therapeutic drugs. MRG0
Livzon Pharmaceutical Group Inc. -B (02157.HK): MRG003 has received FDA breakthrough therapy designation for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
Le Pu Biological -B (02157.HK) issued an announcement on August 5. The company's candidate drug MRG003 (a epidermal growth factor receptor-targeted antibody-drug conjugate ("ADC") candidate drug and the company's core product) has recently been granted Breakthrough Therapy Designation ("BTD") by the US Food and Drug Administration ("FDA") for the treatment of recurrent or metastatic nasopharyngeal carcinoma ("R/M NPC"). Prior to this, MRG003 had already received BTD from the Drug Evaluation Center ("CDE") of the National Medical Products Administration (China).
Express News | Lepu Biopharma Co - Mrg003 Granted Breakthrough Therapy Designation by US FDA
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
One Lepu Biopharma Insider Has Reduced Their Stake
No Data